New Solutions Across Key Markets

A selection of high-performance systems and high-value analytical solutions with an emphasis on pharma and applied markets, were a key feature of Bruker’s booth. Frank H. Laukien, PhD, Bruker President and CEO, commented: "At Pittcon 2017 our commitment to developing state-of-the-art systems and innovative solutions for pharmaceutical, applied, neuroscience and nanoanalysis markets is on full display."

These included the MALDI PharmaPulse 2.0 system enables primary screens of millions of compounds at significantly lower cost, measuring up to 10 different samples per second, a 100- to 1000-fold increase in speed and throughput for mass spectrometry-based, label-free screening, with seamless integration into third-party UHTS robotics solutions.

The BioPharma Compass 2.0is a new solution for biopharma R&D and QC, including wizard-driven workflows for monoclonal antibody and antibody-drug conjugates (ADC) characterisation, intact mass analysis, sequence errors, truncations, substitutions and key post translational modifications, such as glycosylation. Data can be unified from the most relevant and complementary MS methods for the characterization of biologics, MALDI-TOF/TOF and ESI-UHR-QTOF.

A portfolio of microESR spectrometers, offering research-grade results in a compact footprint for applied and industrial applications, included the VERTEX 80v FTIR R&D spectrometer incorporating the vertebra THz extension for combined FTIR and continuous-wave THz spectroscopy.

New in the microscopy imaging and nonoscience category was the NeuraLight 3D™ an advanced system for optogenetics research to decode neural connectivity and networks. This breakthrough in simultaneous, all-optical optogenetic stimulation and multiphoton microscopy imaging was achieved in close collaboration with leaders in neuroscience research at Stanford University, Columbia University and University College London.